Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Aptose Biosciences Inc

Current price
0.61 USD -0.014 USD (-2.26%)
Last closed 0.89 CAD
Sector Healthcare
Industry Biotechnology
Exchange TO
Capitalization 16 136 100 CAD
Yield for 12 month -84.37 %
21.11.2021 - 28.11.2021

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Address: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
MSFT MSFT Microsoft


WallStreet Target Price

42.75 CAD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

Last Year

Current Quarter

Last Quarter

Key Figures APTO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -47 999 727 CAD
Operating Margin TTM
PE Ratio
Return On Assets TTM -115.15 %
PEG Ratio
Return On Equity TTM -361.05 %
Wall Street Target Price 42.75 CAD
Revenue TTM
Book Value 0.009 CAD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -8.34 CAD
Diluted Eps TTM -8.34 CAD
Most Recent Quarter I 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics APTO

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History APTO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor 1:15
Payout Ratio
Last Split Date 06.06.2023
Dividend Date

Stock Valuation APTO

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.3582
Price Book MRQ 3.3313

Financials APTO

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators APTO

For 52 weeks

0.8 CAD 6.91 CAD
50 Day MA 1.24 CAD
Shares Short Prior Month 11 975
200 Day MA 2.41 CAD
Short Ratio 2.33
Shares Short 19 148
Short Percent 0.13 %

Dynamics of changes in the value of assets



1.65 SEK NextCell Pharma AB -0.01 (-4.07%)
Detailed analytics


173.00 JPY Axel Mark Inc 0 (0%)
Detailed analytics


0.010 USD Firefinch Limited 0 (0%)
Detailed analytics


0.010 USD AusCann Group Holdings Ltd -0 (-15.25%)
Detailed analytics


0.33 HKD MOS House Group Ltd 0 (0%)
Detailed analytics